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Brucella spp., are Gram negative bacteria that cause disease by growing within mono-
cyte/macrophage lineage cells. Clinicalmanifestations of brucellosis are immunemediated,
not due to bacterial virulence factors. Acquired immunity to brucellosis has been studied
through observations of naturally infected hosts (cattle, goats), mouse models (mice), and
human infection. Even though Brucella spp. are known for producing mechanisms that
evade the immune system, cell-mediated immune responses drive the clinical manifesta-
tions of human disease after exposure to Brucella species, as high antibody responses are
not associated with protective immunity. The precise mechanisms by which cell-mediated
immune responses confer protection or lead to disease manifestations remain undefined.
Descriptive studies of immune responses in human brucellosis show that TH1 (interferon-
γ-producingT cells) are associated with dominant immune responses, findings consistent
with animal studies. Whether these T cell responses are protective, or determine the dif-
ferent clinical responses associated with brucellosis is unknown, especially with regard
to undulant fever manifestations, relapsing disease, or are associated with responses to
distinct sets of Brucella spp. antigens are unknown. Few data regardingT cell responses in
terms of specific recognition of Brucella spp. protein antigens and peptidic epitopes, either
by CD4+ or CD8+ T cells, have been identified in human brucellosis patients. Addition-
ally because current attenuated Brucella vaccines used in animals cause human disease,
there is a true need for a recombinant protein subunit vaccine for human brucellosis,
as well as for improved diagnostics in terms of prognosis and identification of unusual
forms of brucellosis. This review will focus on current understandings of antigen-specific
immune responses induced Brucella peptidic epitopes that has promise for yielding new
insights into vaccine and diagnostics development, and for understanding pathogenetic
mechanisms of human brucellosis.
Keywords:T cell epitope, immunology, Brucella, zoonotic diseases, systems biology
INTRODUCTION
Cellular mediated immune responses to brucellosis drive a broad
range of manifestations of the disease that vary from subclini-
cal infection (more common with Brucella abortus) to undulant
fever, to focal pyogenic infection, to chronic fatigue syndrome-
like illness (Yingst and Hoover, 2003; Yang et al., 2005). However,
the molecular mechanisms that determine the variable manifes-
tations of Brucella infection remain to be elucidated. Information
on acquired immunity to humanbrucellosis has been accumulated
through observational studies of naturally infected hosts (cattle,
goats), experimental models (mice), and observations of human
disease. Three predominant Brucella species are seen frequently in
human infections: B. melitensis, B. abortus, and B. suis. Of these
three species, B. melitensis infections are most commonly seen
in humans and seem to be the most pathogenic (Pappas et al.,
2005). In the United States, domesticated cattle, which are poten-
tial reservoirs for the organism, are vaccinated against B. abortus
(RB51 or S19); elsewhere (in the Middle East and Latin Amer-
ica), goats and sheep may be vaccinated with Rev-1, an attenuated
strain of B. melitensis. Currently available veterinary vaccines are
comprised of live-attenuated organisms but are unacceptable in
humans because they cause clinical disease (Kinikli et al., 2005;
Durward et al., 2010).
Brucellosis can occur in several forms: acute/subacute (associ-
ated with positive blood cultures, high titer agglutination serolo-
gies), focal (blood culture negative, serologically variable, and
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positive local site culture), and chronic (blood culture negative,
serologically variable but often negative, sometimes bone mar-
row culture positive, often diagnosed clinically in response to
therapy; Jimenez de Bagues et al., 2005). However, it is currently
unknownwhat causes some individuals to have the acute form and
some to progress and develop chronic disease. As hypothesized in
this review and elsewhere, it seems probable that immunogenet-
ics of cell-mediated immune responses to Brucella protein anti-
gens determines clinical manifestations and outcome. Sometimes,
despite treatment for brucellosis, there are still some bacterial foci
that may persist despite antibiotics or Brucella DNAemia may per-
sist, presumably because of deficient T cell activation of infected
macrophage/dendritic cells (DCs; Vrioni et al., 2008). Additional
mechanisms may also include altered innate immune responses
determined by the pathogenetic properties of the bacteria them-
selves. There have been studies demonstrating that Brucella epi-
topes can include those recognized by peptide-specific CD8+ T
cells associated with protective responses at least in a mouse model
(Durward et al., 2010). While there has been an experimental
interferon-gamma release assay developed for bovine brucellosis,
there has not been one developed for human infection to dif-
ferentiate immune responses associated with different forms of
brucellosis, to definitely diagnose previous exposure, or identify
targets of protective immunity. Understanding the precise molec-
ular targets (protein, peptidic epitope) of T cell-mediated immune
responses has the promise to translate to further investigations into
new vaccine and diagnostic Brucella T cell epitopes, and their role
in specific T cell-mediated responses.
T CELL CYTOKINE RESPONSES TO BRUCELLA INFECTION
Infections may occur after ingestion or inhalation of Brucellae
that penetrate mucosal surface such as the upper respiratory or
gastrointestinal mucosa via lymphoid cells. Once the bacteria are
phagocytosed bymacrophages,DCs (Billard et al., 2007), andother
antigenpresenting cells (APCs), approximately 40–50%of the bac-
teria resist digestion within these cells. B. abortus and B. melitensis
that have smooth LPS (with intactO-antigen chain) are able to sur-
vive better intracellularly than B. canis that has rough LPS (lacks
O-antigen side chain; Vrioni et al., 2008). Brucella spp. LPS is also
composed of longer carbon chains (C28) as apposed to the usual
12–16 carbons in the LPS from Enterobacteriaceae. In addition,
Brucella spp. produce proteins (e.g., Vi antigen), which create a
capsule around the LPS, therefore limiting it to have contact with
TLR4 receptors (Lapaque et al., 2005; Tsolis et al., 2008). In addi-
tion, the domain for the flagellin protein in Brucella spp. does
not stimulate TLR5 receptors, and is another way for the bacteria
to evade the immune system during early infection (Tsolis et al.,
2008). These areas are conserved in all Brucella spp. and to others
in the same family to evade detection by the immune system dur-
ing the infection and possibly allowing the bacteria to persist in
the reticuloendothelial system (Tsolis et al., 2008; Barquero-Calvo
et al., 2009).
After initial encounter with Brucella antigens, APCs produce
interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor
alpha (TNF-α), and gamma-interferon (IFN-γ) initiating innate
immune responses (including natural killer cells) that may limit
the initial spread of organisms. Infected APC in which organisms
residing within unactivated phagolysosomes are likely to present
some subset of peptidic Brucella antigens (hitherto unknown)
to CD4+ and CD8+ cells, and thus inducing a TH1 response
associated with IFN-γ release. The functional consequences of
antigen-specific IFN-γ release is unclear but does not lead to
elimination of organisms during active, symptomatic infection
and likely results in clinical symptomatology (i.e., fever, sweating,
weight loss). Clonal T cell expansion is initiated with production
of interleukin-2 (IL-2) and interleukin-12 (IL-12), which initiates
a CD8+ cytotoxic response on Brucella-infected cells. Infected
macrophages produce IL-12 and IFN-γ which regulate antigen
presentation and may contribute to the limitation of intracellu-
lar bacterial replication through unknown mechanisms (Akbulut
et al., 2005). Data also suggest that Brucella spp. also modify the
initial immune response once phagocytosed into APCs. To sur-
vive within APCs, Brucella use certain gene products to subvert
certainphagocyte intracellular processes,particularly phagosome–
lysosome fusion which would be associated with bacterial killing.
One way that the organism survives within APCs is through Bru-
cella-containing vacuoles (BCVs), which the organism secretes
Sar1, a critical protein which allows the organism to replicate
within these vacuoles (Celli et al., 2005). CD64, also known
as FcγRI, is a macrophage-expressed gene whose expression is
down-regulated in B. melitensis infections (Lapaque et al., 2005),
reflecting the reduction of antigen processing in Brucella-infected
APCs and possibly inhibiting the killing of infected cells initiated
by CD4+ and CD8+ T cells. This mechanism may be impor-
tant for decreasing superoxide and reactive nitrogen compounds
as another pathogen-associated localized immunosuppression.
Other gene products such as cystatin C, serpina3c, and Gas2 (nat-
ural peptidase inhibitors) appear to alter macrophage chemotaxis,
cell migration, and proliferation,which may further allow Brucella
to avoid immune surveillance and lead to enhanced multiplica-
tion (Lapaque et al., 2005). Decreased transcription of Cyp4a10
is thought to be associated with the reduction of oxidative stress
that creates an environment conducive to bacterial proliferation.
Prkca is another macrophage-associated gene potentially modu-
lated during Brucella infection, who functions includes regulating
phagosome–lysosome fusion and intracellular vesicle and reactive
oxygen species (ROS) generation. Prkca expression is dramati-
cally reduced in Brucella-infected macrophages, and interestingly,
has been shown to be regulated by other intracellular pathogens
such as Salmonella, Leishmania, and Legionella. All these mech-
anisms contribute to allowing Brucellae to survive within the
intracellular environment, and evade not only the innate immu-
nity, but CD4+- and CD8+-mediated host cell killing (Covert
et al., 2009).
Alteration of T cell function may be key to explaining the
clinico-pathological manifestations of chronic or relapsing bru-
cellosis. Specifically, a decreased TH1 cytokine response by APCs
(with decreased activation of cytotoxic T cells via IFN-γ, IL-12,
and possibly IL-17 (Pasquevich et al., 2010), and toward a TH2
response (which decreases phagocyte function and reduced cyto-
toxic response via IL-4, IL-5, and IL-10; Jimenez de Bagues et al.,
2005). These infected cells fail to produce IFN-γ, and decrease
clonal expansion of Brucella-specific CD4+ T cells. Subsequently,
Brucella-specific CD8+ T cells would not initiate destruction
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of infected cells by perforin and granzyme injection (cell lysis)
or through stimulation of FAS ligand (cellular apoptosis; Yingst
and Hoover, 2003; Skendros et al., 2008). Based on these con-
siderations, the unusual and diverse manifestations of chronic
and relapsing brucellosis could be related to several potential
immunopathogenic mechanisms: an ineffective CD4+ effector
response, a down-regulated CD8+ T cell response or a continued,
established TH2 response, each of which could result in an incom-
plete resolution of the infection (Giambartolomei et al., 2004). In
comparing cytokine responses in patients with acute and chronic
brucellosis, before and after treatment,Akbulut et al. (2005) found
that in chronic brucellosis, both the absolute number of CD4+
cells and the quantitative secretion of IFN-γ were reduced. Rafiei
et al. (2006) confirmed these results, and further demonstrated
that IL-13 is increased in chronic brucellosis, further demon-
strating the initial association of TH1 cytokine responses with
acute brucellosis illness, which gradually becomes TH2 cytokine
dominant. These observations suggest that once acute brucellosis
has resolved, that both the number of CD4+ cells and CD4+
functional response is reduced. Whether antigen-specific mem-
ory CD4+ cells are produced during acute or chronic brucellosis
remains to be determined (Moreno-Lafont et al., 2002; Akbulut
et al., 2005; Kinikli et al., 2005). Recently Elfaki and Al-Hokail
observed that mice deficient in β2-microglobulin produced an
impaired CD8+ response associated with increased Brucella bac-
terial load and decreased clearance (Moreno-Lafont et al., 2002;
Elfaki and Al-Hokail, 2009). Extrapolating such results to human
disease, chronic or relapsing brucellosis might be explained in that
CD69 expression on both CD4+ T cells and CD8+ T cells are
significantly decreased in this patient subset. Further experimen-
tation indicates that there is an unknown individual effect on the
immune system after an episode of acute brucellosis, and therefore
one develop chronic and relapsing brucellosis.
BRUCELLA PROTEINS RECOGNIZED IN HUMAN IMMUNE
RESPONSES
Epitopes are the molecular subset of any macromolecule recog-
nized by antibodies, B cells, T cells, and NK cells. T cells recognize
peptides generally of 8–20 amino acids bound to MHC mole-
cules (HLA Class I associated with CD8+ T cells; HLA Class II
associated with CD4+ T cells) presented on the surface of a B
cell, macrophage or dendritic cell (Yang et al., 2005). Non-classical
MHC molecules also present non-peptidic epitopes such as glycol-
ipids to non-restricted lymphocytes, particularly NK cells. There
are only a few studies in the literature that have demonstrated
either a humoral or cellular response to Brucella epitopes. The
epitopes of greatest interest to date include Bp26 (a periplasmic
protein), Trigger Factor (a chaperone protein; Yang et al., 2005),
and the outer membrane lipoproteins such as Omp 10, 16, and
19 (Tibor et al., 1999). Interestingly, these antigens, especially the
outer membrane lipoproteins, appear to be potent in inducing
cytokine responses from memory T cells. In contrast, Brucella
LPS and Brucella DNA do not elicit intense immune responses
(Giambartolomei et al., 2004; Vrioni et al., 2008). Previous vac-
cine studies in mice have used some of these outer membrane
epitopes (Pasquevich et al., 2010) as well as certain enzymes such
as Cu–Zn superoxide dismutase (Singha et al., 2008). Yet, these
were not demonstrated to offer protection for humans or T cell
cytokine release assays to prove their efficacy.
These antigens have been identified in both B. melitensis and B.
abortus. Bp26 andTrigger Factor have been shown to be recognized
by the immune system (Yang et al., 2005), yetwith a reduced activa-
tion in patients with chronic/relapsing brucellosis. Recently, Liang
et al. (2010, 2011) reported comprehensive systems biology analy-
ses of human antibody responses in acute B. melitensis brucellosis
in Peru. A collection of sera isolated from individuals from one
of the following groups was used to probe large scale B. melitensis
protein microarrays including a ∼1400 proteins array and 3300
proteins array representing nearly the entire encoded proteome:
Brucella blood culture positive, blood culture negative with posi-
tive Rose Bengal, blood culture negativewith negative Rose Bengal,
and two naïve groups (from both American and Peruvian individ-
uals.) Sets of proteins that differentiated acutely infected from
uninfected patient groups were identified that were recognized by
patient IgG responses. These Brucella protein epitopes were then
further separated by the patient groups which recognized them, as
some were only recognized by culture positive or culture negative
patients/Rose Bengal positive patients compared to naïve patients
(Table 1), others cross react in both the culture positive patients
and the naïve patients (Table 2) and some antigens produced a
positive response in the culture positive group but not the cul-
ture negative group/Rose Bengal positive group (Table 3). This
broad spectrum of antibody responses demonstrates the differ-
ences between in the manner that these groups respond to Brucella
protein epitopes. Interestingly, some of the epitopes mentioned
previously (i.e., Bp 26) produced a strong antibody response by
Peruvian brucellosis patients, who were culture positive or culture
negative patients/Rose Bengal positive patients. These antibody
responses could reflect the substantial differences,which these pro-
tein epitopes have on the immune system activation, and a large
number of antigens recognized by brucellosis patients were iden-
tified which have yet to be studied or have limited understanding
of their function.
There could be a potential difference in the antibody responses
compared to cytokine release assays for these specific epitopes,
which produced antibody responses. Based on unpublished data,
Bp26,which gave a strong antibody response,does not give a strong
TH1 response; VirB8 does generate a strong TH1 response, yet
does not give a particularly strong antibody response. The use
of an epitope database has previously been used for Mycobacte-
ria tuberculosis, and other infections by estimating the immune
responses to epitopes associated with a certain organism (Blythe
et al., 2007). A complete cytokine release assay for the entire
brucellar proteome has not been undertaken. Based on the fact
that antibody production is not protective in chronic brucellosis,
we must conclude that T cell assays would be a more appro-
priate method to pursue with regards to not only diagnostic
purposes, but for development of a recombinant protein vaccine
as well.
CONCLUSION
Brucella spp. are important intracellular human and animal
pathogens associated with fascinating mechanisms of immune
modulation and subversion of APCs as an intrinsic mechanism
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Table 1 | Serodiagnostic antigens for culture+ and culture−/Rose Bengal+ vs. Peruvian Naive.
LocusTag/Acc#/Ch#; gene position Function Protein mass (kDa)
BMEI0536 Periplasmic immunogenic protein (bp26) 26,552
LPS-BM-0.1 LPS None
BMEII1048 60 kDa chaperonin 57,462
BMEI0805 Putative uncharacterized protein 11,217
BMEII0032 Type IV secretion system protein; VirB8 26,446
BMEI1330 Probable serine protease do-like 53,514
BMEI0855 Pyruvate dehydrogenase e1 component, β-subunit 48,954
BMEI0228 Lema protein 23,260
BMEI0340 Outer membrane lipoprotein omp16 18,233
BMEI1890 Transporter 34,705
BMEI1077 Immunogenic membrane protein yajC 12,560
BMEII0017 Outer membrane lipoprotein omp10 13,260
BMEI0324 Chemotaxis motb protein 38,302
BMEI0856 Dihydrolipoamide acetyltransferase component of PyDH complex 46,721
BMEI1980 DNA protection during starvation protein 19,903
BMEI0141 Dihydrolipoamide succinyltransferase 42,911
BMEI0135 Outer membrane lipoprotein omp19 17,604
BMEI1060 Outer membrane protein 27,290
BMEI0786 Outer membrane protein (integral) 24,423
BMEI0587 Competence lipoprotein 34,770
BMEII0497 Enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase/3-hydroxybutyryl-CoA epimerase 80,197
BMEI1185 K(+)-insensitive pyrophosphate-energized proton pump 73,341
BMEII0073 Putative uncharacterized protein 11,277
BMEI0973 Putative uncharacterized protein 16,613
BMEI0962 Membrane lipoprotein lipid attachment site containing protein 19,837
BMEII0589 6,7-dimethyl-8-ribityllumazine synthase 2 (riboflavin biosynthesis) 17,356
BMEII0691 Putative binding protein 69,388
BMEI0810 Putative membrane protein 29,529
BMEI0339 Acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha 35,013
BMEI0368 Putative uncharacterized protein 12,741
BMEII0704 Bacterioferritin 18,659
BMEI0830 Outer membrane protein 85,919
BMEII1015 Sensor protein (kinase transferase) 48,811
BMEI0503 Acyl-CoA hydrolase 14,555
Table 2 | Cross-reactive antigens for culture+ or culture−/Rose Bengal+ vs. Peruvian Naïve (negative controls).
LocusTag/Acc#/Ch#; gene position Function Protein mass (kDa)
BMEI1079 Putative outer membrane lipoprotein 43,604
BMEI1082 Seryl-tRNA(Ser/Sec) synthetase 47,520
BMEI1084 Sec-independent protein translocase protein tatA/E homolog 7,999
BMEII0010 Hypothetical membrane associated protein 67,136
BMEI1033 Putative uncharacterized protein 23,107
BMEII0917 Putative uncharacterized protein 17,923
BMEII1111 Putative uncharacterized protein 16,629
BMEII0040 Glutamate synthase (large chain) 173,600
BMEII0356 Galactonate dehydratase 66,751
BMEI1382 Betaine aldehyde dehydrogenase 52,035
of the diseases that they cause. New systems biology analyses of
antigens recognized by human immune responses in brucellosis
have identified large numbers of protein antigens with potential
for understanding mechanisms of pathogenesis and immune eva-
sion and may point the way toward novel vaccine and diagnostic
approaches. These approaches have generalized applicability to the
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Table 3 | Serodiagnostic antigens for culture+ vs. culture−/Rose Bengal+.
LocusTag/Acc#/Ch#; gene position Function Protein mass (kDa)
BMEII0173 Putative uncharacterized protein 11,277
BMEII0029 Type IV secretion system protein virB5 26,810
BMEII0182 Putative uncharacterized protein 8,718
BMEII0054 Putative uncharacterized protein 5,237
BMEII1049 Putative uncharacterized protein 7,955
BMEII0558 Putative uncharacterized protein 7,596
BMEII0532 Hypothetical membrane associated protein 7,916
BMEII0892 Putative uncharacterized protein 6,762
BMEI1502 Alkaline phosphatase like protein 21,488
BMEII0720 Transcriptional regulator 7,304
analysis of T cell responses associated chronic bacterial, fungal and
parasitic infections other than Brucella.
ACKNOWLEDGMENTS
This work was partially supported by grant K24AI068903,
3U01AI075420, AI087164, and T32AI007036 from the United
States Public Health Service, National Institutes of Health. We
would like to thank Ms. Paula Maguina of UC San Diego, who
made contributions to both research management and interna-
tional collaboration. Finally, we would like to thank all of the
patients both in the USA and in Peru for their participation in this
study.
REFERENCES
Akbulut,H. H., Kilic, S. S., Bulut,V., and
Ozden,M. (2005). Determination of
intracellular cytokines produced by
Th1 and Th2 cells using flow cytom-
etry in patients with brucellosis.
FEMS Immunol. Med. Microbiol. 45,
253–258.
Barquero-Calvo, E., Conde-Alvarez, R.,
Chacon-Diaz, C., Quesada-Lobo, L.,
Martirosyan, A., Guzmán-Verri, C.,
Iriarte, M., Mancek-Keber, M., Jer-
ala, R., Gorvel, J. P., Moriyón,
I., Moreno, E., and Chaves-Olarte,
E. (2009). The differential inter-
action of Brucella and ochrobac-
trum with innate immunity reveals
traits related to the evolution of
stealthy pathogens. PLoS ONE 4,
e5893. doi: 10.1371/journal.pone.
0005893
Billard, E., Dornand, J., and Gross,
A. (2007). Interaction of Bru-
cella suis and Brucella abortus
rough strains with human den-
dritic cells. Infect. Immun. 75,
5916–5923.
Blythe,M. J., Zhang,Q.,Vaughan, K., de
Castro, R. Jr., Salimi, N., Bui, H. H.,
Lewinsohn,D.M.,Ernst, J. D.,Peters,
B., and Sette, A. (2007). An analy-
sis of the epitope knowledge related
to Mycobacteria. Immunome Res.
3, 10.
Celli, J., Salcedo, S. P., and Gorvel, J.
P. (2005). Brucella coopts the small
GTPase Sar1 for intracellular repli-
cation. Proc. Natl. Acad. Sci. U.S.A.
102, 1673–1678.
Covert, J., Mathison, A. J., Eskra, L.,
Banai, M., and Splitter, G. (2009).
Brucella melitensis, B. neotomae and
B. ovis elicit common and distinc-
tive macrophage defense transcrip-
tional responses. Exp. Biol. Med.
(Maywood). 234, 1450–1467.
Durward, M. A., Harms, J., Magnani,
D. M., Eskra, L., and Splitter, G. A.
(2010). Discordant Brucella meliten-
sis antigens yield cognate CD8+
T cells in vivo. Infect. Immun. 78,
168–176.
Elfaki, M. G., and Al-Hokail, A. A.
(2009). Transforming growth fac-
tor beta production correlates with
depressed lymphocytes function in
humans with chronic brucellosis.
Microbes Infect. 11, 1089–1096.
Giambartolomei, G. H., Zwerdling, A.,
Cassataro, J., Bruno,L., Fossati,C.A.,
and Philipp, M. T. (2004). Lipopro-
teins, not lipopolysaccharide, are the
key mediators of the proinflamma-
tory response elicited by heat-killed
Brucella abortus. J. Immunol. 173,
4635–4642.
Jimenez de Bagues, M. P., Dudal, S.,
Dornand, J., and Gross, A. (2005).
Cellular bioterrorism: how Bru-
cella corrupts macrophage phys-
iology to promote invasion and
proliferation. Clin. Immunol. 114,
227–238.
Kinikli, S., Turkcapar, N., Kucukay,
M. B., Keskin, G., and Kinikli, G.
(2005). In vitro nonspecific mito-
genic response of T-cell subsets
in acute and chronic brucellosis.
Diagn. Microbiol. Infect. Dis. 52,
229–233.
Lapaque, N., Moriyon, I., Moreno, E.,
and Gorvel, J. P. (2005). Brucella
lipopolysaccharide acts as a viru-
lence factor. Curr. Opin. Microbiol.
8, 60–66.
Liang, L., Leng, D., Burk, C., Nakajima-
Sasaki, R., Kayala, M. A., Atluri,
V. L., Pablo, J., Unal, B., Ficht, T.
A., Gotuzzo, E., Saito, M., Morrow,
W. J., Liang, X., Baldi, P., Gilman,
R. H., Vinetz, J. M., Tsolis, R. M.,
and Felgner, P. L. (2010). Large
scale immune profiling of infected
humans and goats reveals differen-
tial recognition of Brucella meliten-
sis antigens. PLoS Negl. Trop. Dis. 4,
e673.
Liang, L., Tan, X., Juarez, S., Villaverde,
H., Pablo, J., Nakajima-Sasaki, R.,
Gotuzzo, E., Saito, M., Hermanson,
G., Molina, D., Felgner, S., Mor-
row, W. J., Liang, X., Gilman, R. H.,
Davies, D. H., Tsolis, R. M., Vinetz,
J. M., and Felgner, P. L. (2011). Sys-
tems biology approach predicts anti-
body signature associated with Bru-
cella melitensis infection in humans.
J. Proteome Res. 10, 4813–4824.
Moreno-Lafont, M. C., Lopez-Santiago,
R., Zumaran-Cuellar, E., Paredes-
Cervantes, V., López-Merino, A.,
Estrada-Aguilera, A., and Santos-
Argumedo, L. (2002). Antigen-
specific activation and proliferation
of CD4+ and CD8+ T lymphocytes
from brucellosis patients. Trans. R.
Soc. Trop. Med. Hyg. 96, 340–347.
Pappas, G., Akritidis, N., Bosilkovski,
M., and Tsianos, E. (2005). Bru-
cellosis. N. Engl. J. Med. 352,
2325–2336.
Pasquevich, K. A., Garcia Samartino,
C., Coria, L. M., Estein, S. M.,
Zwerdling, A., Ibañez, A. E., Bar-
rionuevo, P.,Oliveira, F. S., Carvalho,
N. B., Borkowski, J., Oliveira, S. C.,
Warzecha, H., Giambartolomei, G.
H., and Cassataro, J. (2010). The
protein moiety of Brucella abortus
outer membrane protein 16 is a
new bacterial pathogen-associated
molecular pattern that activates
dendritic cells in vivo, induces a
Th1 immune response, and is a
promising self-adjuvanting vaccine
against systemic and oral acquired
brucellosis. J. Immunol. 184,
5200–5212.
Rafiei,A.,Ardestani, S. K.,Kariminia,A.,
Keyhani,A.,Mohraz,M.,Amirkhani,
A. (2006). Dominant Th1 cytokine
production in early onset of human
brucellosis followed by switching
towards Th2 along prolongation of
disease. J Infect. 53, 315–324.
Singha, H., Mallick, A. I., Jana, C., Isore,
D. P., Goswami, T.K., Srivastava, S.
K., Azevedo, V. A., Chaudhuri, P.,
and Owais, M. (2008). Escherio-
somes entrapped DNA vaccine co-
expressing Cu-Zn superoxide dis-
mutase and IL-18 confers protection
against Brucella abortus. Microbes
Infect. 10, 1089–1096.
Skendros, P., Sarantopoulos, A., Tselios,
K., and Boura, P. (2008). Chronic
brucellosis patients retain low fre-
quency of CD4+ T-lymphocytes
expressing CD25 and CD28 after
Escherichia coli LPS stimulation of
PHA-cultured PBMCs. Clin. Dev.
Immunol. 2008, 327346.
Tibor, A., Decelle, B., and Letesson, J.
J. (1999). Outer membrane proteins
Frontiers in Cellular and Infection Microbiology www.frontiersin.org February 2012 | Volume 2 | Article 1 | 5
Cannella et al. Human brucellosis immunology
Omp10, Omp16, and Omp19 of
Brucella spp. are lipoproteins. Infect.
Immun. 67, 4960–4962.
Tsolis, R. M., Young, G. M., Solnick,
J. V., and Baumler, A. J. (2008).
From bench to bedside: stealth of
enteroinvasive pathogens. Nat. Rev.
Microbiol. 6, 883–892.
Vrioni, G., Pappas, G., Priavali, E., Gart-
zonika,C., andLevidiotou,S. (2008).
An eternal microbe: Brucella DNA
load persists for years after clinical
cure. Clin. Infect. Dis. 46, e131–e136.
Yang, X., Hudson, M., Walters, N.,
Bargatze, R. F., and Pascual, D.
W. (2005). Selection of protective
epitopes for Brucella melitensis by
DNA vaccination. Infect. Immun. 73,
7297–7303.
Yingst, S., and Hoover, D. L. (2003). T
cell immunity to brucellosis. Crit.
Rev. Microbiol. 29, 313–331.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 10 October 2011; accepted: 11
January 2012; published online: 01 Feb-
ruary 2012.
Citation: Cannella AP, Tsolis RM,
Liang L, Felgner PL, Saito M, Sette
A, Gotuzzo E and Vinetz JM (2012)
Antigen-specific acquired immunity in
human brucellosis: implications for diag-
nosis, prognosis, and vaccine develop-
ment. Front. Cell. Inf. Microbio. 2:1. doi:
10.3389/fcimb.2012.00001
Copyright © 2012 Cannella, Tsolis,
Liang , Felgner, Saito, Sette, Gotuzzo and
Vinetz. This is an open-access article
distributed under the terms of the Cre-
ative Commons Attribution Non Com-
mercial License, which permits non-
commercial use, distribution, and repro-
duction in other forums, provided the
original authors and source are credited.
Frontiers in Cellular and Infection Microbiology www.frontiersin.org February 2012 | Volume 2 | Article 1 | 6
